Marker Therapeutics (MRKR) Fundamental Analysis: Revenue, Earnings & Valuation

3.32 / 10

Netural

Fundamental analysis rates MRKR at 3.3/10, indicating weakness. Revenue‑MV and Profit‑MV are modestly positive, yet Asset‑MV is low, current‑asset turnover is poor, and tax‑to‑profit ratio is weak, rendering the overall fundamentals challenging.

Analysis Checks(7/10)

Revenue-MV

Value-1.36

Score2/3

Weight17.39%

1M Return8.05%

Inventory turnover ratio

Value106.57

Score3/3

Weight15.05%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score2/3

Weight3.19%

1M Return1.67%

Profit-MV

Value0.68

Score2/3

Weight14.16%

1M Return6.36%

Income tax / Total profit (%)

Value0.12

Score1/3

Weight0.35%

1M Return0.21%

Current assets turnover ratio

Value0.17

Score0/3

Weight-2.64%

1M Return-1.61%

Fixed assets turnover ratio

Value9771.06

Score3/3

Weight3.00%

1M Return1.76%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight7.48%

1M Return4.08%

Asset-MV

Value-0.55

Score1/3

Weight28.16%

1M Return11.48%

Cash-MV

Value0.03

Score2/3

Weight13.87%

1M Return6.19%

Is MRKR fundamentally strong?

MRKR scores 3.32/10 on fundamentals and holds a Fair valuation at present. Backed by its -68.81% ROE, -342.96% net margin, -1.84 P/E ratio, 1.33 P/B ratio, and 33.61% earnings growth, these metrics solidify its Netural investment rating.